Bayer/Regeneron's Eylea heading for early DME market entry
This article was originally published in Scrip
Regeneron and Bayer's eye product Eylea (aflibercept) has notched up Phase III success in a fourth indication, diabetic macular edema (DME). Both companies expect to file for expanded approval of the drug in this indication this year – Regeneron in the US and Bayer in the EU. The US filing will come about a year ahead of schedule, Regeneron noted.